Vascular valves having implanted and target configurations and methods of preparing the same

• US 7,458,987 B2
• Filed: 10/27/2005
• Issued: 12/02/2008
• Est. Priority Date: 10/29/2004
• Status: Active Grant

• Current Assignee: Cook Medical Incorporated (Cook Group Incorporated)
• Original Assignee: Cook Incorporated (Cook Group Incorporated)
• Inventors: Pavcnik, Dusan, Case, Brian C., Flagle, Jacob A., Obermiller, F. Joseph, Garrison, Michael L.
• Primary Examiner(s): GHERBI, SUZETTE JAIME J
• Application Number:
  US11/260,770
• Publication Number:
  US 20060212111A1
• Time in Patent Office: 1,132 Days
• Field of Search: 623 124- 126, 623/1.42, 623 213- 219
• US Class Current: 623/1.24
• CPC Class Codes: A61F 2/2418 Scaffolds therefor, e.g. support stents
• CPC Class Codes: A61F 2/2436 Deployment by retracting a sheath
• CPC Class Codes: A61F 2/2475 Venous valves
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2220/0016 with sharp anchoring protrusions, e.g. barbs, pins, spikes
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body

Abstract

Described are vascular valve devices for implantation in a patient. The vascular valve devices are designed to compensate for the retraction characteristics of a remodelable material used to form one or more leaflets. Alternatively, or in addition, the devices are designed to reduce retraction of the remodelable leaflet-forming material. Further described are methods for preparing and using these vascular valve devices.

Claims

1. A vascular valve device for implantation in a patient to form two or more leaflets including tissue of the patient in a target configuration, the valve device comprising:

a frame having a longitudinal axis;

a remodelable covering that retracts upon remodeling, the remodelable covering attached to the frame in a first configuration for implantation, the first configuration having two or more leaflet-forming portions formed from the remodelable covering;

said first configuration adapted wherein upon a remodeling of the two or more leaflet-forming portions and consequent retraction, two or more leaflets comprising tissue of the patient in the target valve configuration are formed;

wherein said first configuration for implantation provides a first coaptation path along which the two or more leaflet-forming portions coapt in a closed condition of the valve device, said first coaptation path extending transverse to the longitudinal axis of the frame, and wherein an excess of the remodelable covering provided in a direction transverse to the longitudinal axis of said frame causes said first coaptation path to be tortuous;

wherein said target configuration provides a target coaptation path along which the two or more leaflets coapt in a closed condition of the valve device, said target coaptation path extending transverse to the longitudinal axis of the frame, and wherein said target coaptation path is less tortuous than said first coaptation path due to remodeling and consequent retraction of said leaflet-forming portions of said remodelable covering.

2. The vascular valve device of claim 1, wherein the remodelable covering is attached to the frame such that fibers of the remodelable covering are oriented substantially parallel to a valve orifice created by the one or more leaflets.

3. The vascular valve device of claim 1, wherein each leaflet-forming portion comprises a separate piece of said remodelable covering.

4. The vascular valve device of claim 1, wherein the remodelable covering has been pre-conditioned by stretching.

5. The vascular valve device of claim 1, wherein an excess of remodelable covering is also provided at least in a direction substantially parallel to the longitudinal axis of the frame.

6. The vascular valve device of claim 1, wherein an excess of remodelable covering is also provided at least in a direction substantially perpendicular to the valve orifice.

7. The vascular valve device of claim 1, wherein the remodelable covering is treated with an agent that reduces retraction of the covering upon remodeling.

8. The vascular valve device of claim 7, wherein the remodelable covering is treated with a crosslinking agent.

9. The vascular valve device of claim 8, wherein the remodelable covering is crosslinked by glycation.

10. The vascular valve device of claim 7, wherein the remodelable covering is crosslinked by subjecting the covering to energy.

11. The vascular valve device of claim 10, wherein the energy is provided by subjecting the covering to ultraviolet light.

12. The vascular valve device of claim 10, wherein the energy is provided by subjecting the covering to heat.

13. The vascular valve device of claim 7, wherein the remodelable covering is treated with an anti-proliferative agent.

14. The vascular valve device of claim 13, wherein the anti-proliferative agent comprises Paclitaxel.

15. The vascular valve device of claim 13, wherein the anti-proliferative agent comprises a microtubule-inhibiting agent.

16. The vascular valve device of claim 1, wherein the remodelable covering comprises a collagenous extracellular matrix (ECM)

17. The vascular valve device of claim 16, wherein the ECM comprises a member selected from the group consisting of pericardium, submucosa, basement membrane, and dura mater.

18. The vascular valve device of claim 17, wherein the ECM comprises submucosa.

19. The vascular valve device of claim 1, wherein the frame comprises a wire structure.

20. The vascular valve device of claim 1, wherein the frame comprises a superelastic material.

21. A vascular valve device for implantation in a patient to form one or more leaflets comprising tissue of the patient, the valve device comprising a remodelable material treated with an agent to reduce retraction of the material upon remodeling and configured to provide one or more leaflet-forming portions that effectively remodel with tissue of the patient to form one or more corresponding leaflets comprising tissue of the patient;

wherein said agent comprises an anti-proliferative agent and the remodelable material is treated by coating the remodelable material with the agent; and

wherein said anti-proliferative agent comprises a microtubule inhibiting agent.

22. The vascular valve device of claim 21, wherein said agent comprises Paclitaxel.

23. The vascular valve device of claim 21, wherein the remodelable material comprises an extracellular matrix (ECM).

24. The vascular valve device of claim 23, wherein the ECM comprises a member selected from the group consisting of pericardium, submucosa, basement membrane, and dura mater.

25. The vascular valve device of claim 24, wherein the ECM comprises submucosa.

26. The vascular valve device of claim 21, wherein the vascular valve device includes a frame to which said one or more leaflet-forming portions are attached.

27. The vascular valve device of claim 26, wherein the frame comprises a superelastic material.

28. A method of preparing a vascular valve device for implantation in a patient, comprising:

providing a frame having a longitudinal axis;

attaching to the frame a remodelable covering material in a first valve configuration having two or more leaflet-forming portions, wherein the remodelable covering material retracts upon remodeling;

said first valve configuration adapted wherein upon implantation of the device and remodeling of the covering material with the patient'"'"'s tissue and consequent retraction, two or more leaflets comprising tissue of the patient in a target valve configuration are formed from the leaflet-forming portions;

wherein said first valve configuration provides a first coaptation path along which the two or more leaflet-forming portions coapt in a closed condition of the valve device, said first coaptation path extending transverse to the longitudinal axis of the frame, and wherein an excess of the remodelable covering provided in a direction transverse to the longitudinal axis of said frame causes said first coaptation path to be tortuous;

wherein said target configuration provides a target coaptation path along which the two or more leaflets coapt in a closed condition of the valve device, said target coaptation path extending transverse to the longitudinal axis of the frame, and wherein said target coaptation path is less tortuous than said first coaptation path due to remodeling and consequent retraction of said leaflet-forming portions of said remodelable covering material.

29. A vascular valve device for implantation in a patient to form multiple leaflets including tissue of the patient in a target configuration, the valve device comprising:

a frame;

a remodelable covering that retracts upon remodeling, the remodelable covering attached to the frame in a first configuration for implantation, the first configuration having multiple leaflet-forming portions formed from the remodelable covering;

said first configuration adapted wherein upon remodeling of the multiple leaflet-forming portions and consequent retraction, multiple leaflets comprising tissue of the patient in the target valve configuration are formed; and

wherein each said leaflet-forming portion comprises a separate piece of said remodelable covering.

30. The vascular valve device of claim 29, wherein the remodelable covering comprises an extracellular matrix (ECM).

31. The vascular valve device of claim 30, wherein the ECM comprises a member selected from the group consisting of pericardium, submucosa, basement membrane, and dura mater.

32. The vascular valve device of claim 31, wherein the ECM comprises submucosa.

33. A vascular valve device for implantation in a patient to form one or more leaflets including tissue of the patient in a target configuration, the valve device comprising:

a frame;

a remodelable covering that retracts upon remodeling, the remodelable covering attached to the frame in a first configuration for implantation, the first configuration having one or more leaflet-forming portions formed from the remodelable covering;

said first configuration adapted wherein upon remodeling of the one or more leaflet-forming portions and consequent retraction, one or more leaflets comprising tissue of the patient in the target valve configuration are formed;

wherein said remodelable covering is treated with an agent that reduces retraction of the covering upon remodeling, wherein said agent is a crosslinking agent, and wherein said crosslinking agent causes said remodelable covering to be crosslinked by glycation.